CELL RECEPTOR DEVELOPS A FUTURE-ORIENTED THERAPY FOR HIGH MEDICAL NEEDS: CANCER AND AUTOIMMUNE DISEASES
Cell Receptor is a small Geneva-based corporation that is building new treatments to prevent cancer metastasis and control autoimmune diseases:
The standard strategy in oncology is to kill the tumor cell itself. The methods used are fraught with serious side effects. The Cell Receptor team has found a way to prevent the proliferation of cancer cells by blocking metabolic steps that have not yet been considered in oncology. We interfere with extracellular-mediated signaling of cell growth via a mechanism upstream of the widely recognized receptor tyrosine kinase at the cell surface - a completely new approach in oncology.
We can significantly improve oncology outcomes with simple and well-tolerated agents. We have the IP. Therefore, our findings will have a profound impact on this medical field.
Growing cells, including tumor cells, need to bind with platelets to grow. Platelets provide the cells with growth factors, help cells evade the immune system, and protect circulating tumor cells against shear stress. We know how to block this contact, thus preventing tumor cell growth and especially metastasis – an urgent unmet need.
See this article: https://www.nature.com/articles/d43747-021-00133-8